{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:56Z","timestamp":1787991416274,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Daiichi Sankyo (China) Holding Co, Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03729-7","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:55:32Z","timestamp":1787990132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct06809764","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jianchun","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglei","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Degan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujie","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"3729_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3729_CR2","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46:221\u201331.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"3729_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1053\/j.semnuclmed.2025.02.009","volume":"55","author":"F Alorfi","year":"2025","unstructured":"Alorfi F, Bomanji J, Bertoletti L, Fraioli F. PET\/MRI in non-small cell lung cancer (NSCLC). Semin Nucl Med. 2025;55:234\u20139.","journal-title":"Semin Nucl Med"},{"key":"3729_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biom14121523","volume":"14","author":"Y Ye","year":"2024","unstructured":"Ye Y, Yu S, Guo T, et al. Epithelial-mesenchymal transition in non-small cell lung cancer management: opportunities and challenges. Biomolecules. 2024;14:1523.","journal-title":"Biomolecules"},{"key":"3729_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2021.0200","volume":"19","author":"JK Sabari","year":"2021","unstructured":"Sabari JK, Heymach JV, Sandy B. Hitting the right spot: advances in the treatment of NSCLC with uncommon EGFR mutations. J Natl Compr Canc Netw. 2021;19:S1\u201311.","journal-title":"J Natl Compr Canc Netw"},{"key":"3729_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102520","volume":"114","author":"Y Yu","year":"2023","unstructured":"Yu Y, Yang Y, Li H, Fan Y. Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges. Cancer Treat Rev. 2023;114:102520.","journal-title":"Cancer Treat Rev"},{"key":"3729_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/1759-7714.13317","volume":"11","author":"F Xu","year":"2020","unstructured":"Xu F, Yang G, Xu H, et al. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Thorac Cancer. 2020;11:679\u201385.","journal-title":"Thorac Cancer"},{"key":"3729_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100260","volume":"6","author":"M Riudavets","year":"2021","unstructured":"Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6:100260.","journal-title":"ESMO Open"},{"key":"3729_CR9","doi-asserted-by":"publisher","first-page":"107327482513475","DOI":"10.1177\/10732748251347572","volume":"32","author":"C Liu","year":"2025","unstructured":"Liu C, Li T, Cui X, et al. Advances and future perspectives of HER2 mutations in non-small lung cancer (NSCLC), especially in China. Cancer Control. 2025;32:10732748251347572.","journal-title":"Cancer Control"},{"key":"3729_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","volume":"8","author":"L Hong","year":"2024","unstructured":"Hong L, Patel S, Drusbosky LM, et al. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. NPJ Precis Oncol. 2024;8:217.","journal-title":"NPJ Precis Oncol"},{"key":"3729_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/annonc\/mdv573","volume":"27","author":"J Mazi\u00e8res","year":"2016","unstructured":"Mazi\u00e8res J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27:281\u20136.","journal-title":"Ann Oncol"},{"key":"3729_CR12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.jtho.2021.06.025","volume":"16","author":"FC Saalfeld","year":"2021","unstructured":"Saalfeld FC, Wenzel C, Christopoulos P, et al. Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations. J Thorac Oncol. 2021;16:1952\u20138.","journal-title":"J Thorac Oncol"},{"key":"3729_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","volume":"14","author":"R Dziadziuszko","year":"2019","unstructured":"Dziadziuszko R, Smit EF, Dafni U, et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase\u00a0II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019;14:1086\u201394.","journal-title":"J Thorac Oncol"},{"key":"3729_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1200\/JCO.21.01113","volume":"40","author":"YY Elamin","year":"2022","unstructured":"Elamin YY, Robichaux JP, Carter BW, et al. Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase\u00a0II trial. J Clin Oncol. 2022;40:702\u20139.","journal-title":"J Clin Oncol"},{"key":"3729_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554:189\u201394.","journal-title":"Nature"},{"key":"3729_CR16","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","volume":"26","author":"MG Kris","year":"2015","unstructured":"Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase\u00a0II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26:1421\u20137.","journal-title":"Ann Oncol"},{"key":"3729_CR17","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/j.jtho.2023.09.210","volume":"18","author":"X Le","year":"2023","unstructured":"Le X, Prelaj A, Baik C, et al. MA13.09 Efficacy and safety of poziotinib in HER2 exon 20 insertion NSCLC patients who received at least 2 previous systemic therapies. J Thorac Oncol. 2023;18:S147\u20138.","journal-title":"J Thorac Oncol"},{"key":"3729_CR18","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1200\/JCO.20.00297","volume":"38","author":"C Zhou","year":"2020","unstructured":"Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase\u00a0II study. J Clin Oncol. 2020;38:2753\u201361.","journal-title":"J Clin Oncol"},{"key":"3729_CR19","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase\u00a0II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852\u201363.","journal-title":"J Clin Oncol"},{"key":"3729_CR20","doi-asserted-by":"crossref","unstructured":"Cheng Y, Wu L, Fang Y, et al. Abstract CT248: trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Res. 2024;84(7_Supplement):CT248.","DOI":"10.1158\/1538-7445.AM2024-CT248"},{"key":"3729_CR21","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","volume":"20","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Goto Y, Kubo T, et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase\u00a02 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol. 2025;20:1814\u201328.","journal-title":"J Thorac Oncol"},{"key":"3729_CR22","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.1016\/j.jtho.2025.09.706","volume":"20","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Li D, Wu L, et al. P2.10.12 Trastuzumab deruxtecan in patients from China with pretreated HER2-mutant NSCLC: final results from the DESTINY-Lung05 study. J Thorac Oncol. 2025;20:S376\u20137.","journal-title":"J Thorac Oncol"},{"key":"3729_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"3729_CR24","doi-asserted-by":"publisher","first-page":"S995","DOI":"10.1016\/j.annonc.2022.07.1104","volume":"33","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al. 976P Phase\u00a0II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): registrational data from DESTINY-Lung01. Ann Oncol. 2022;33:S995\u20136.","journal-title":"Ann Oncol"},{"key":"3729_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241\u201351.","journal-title":"N Engl J Med"},{"key":"3729_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","volume":"29","author":"GU Mehta","year":"2024","unstructured":"Mehta GU, Vellanki PJ, Ren Y, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist. 2024;29:667\u201371.","journal-title":"Oncologist"},{"key":"3729_CR27","volume-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of non-small cell lung cancer 2025","author":"Chinese Society of Clinical Oncology, Committee of Experts on Non-Small Cell Lung Cancer","year":"2025","unstructured":"Chinese Society of Clinical Oncology, Committee of Experts on Non-Small Cell Lung Cancer. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of non-small cell lung cancer 2025. Beijing: People\u2019s Medical Publishing House; 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03729-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:55:33Z","timestamp":1787990133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":27,"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03729-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Si Si is an employee of Daiichi Sankyo (China) Holdings Co., Ltd. at the time of this study. Jianchun Duan, Minglei Zhuo, Chunxia Su, Yibing Liu, Lifeng Wang, Nong Yang, Baoshan Cao, Mingming Hu, Shi Jin, Hui Li, Xiaoyan Li, Yueyin Pan, Jie Hu, Degan Lu, Chuanhao Tang, Bin Yang, Yunjian Huang, Guanming Jiang, Wen Li, Sujie Ni, Wang Sheng, Kejing Tang, Jing Wang, Qiming Wang, Zhijie Wang and Jie Wang declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has obtained approval from the Institutional Review Board and Human Research Ethics Committee of the leading site Shanxi Provincial Cancer Hospital (approval No. YW2024233), and all the participating sites prior to the start of the study in accordance with local laws, regulations and requirements of relevant organizations. The study is conducted in accordance with the Declaration of Helsinki, and written informed consent is obtained from all patients prior to the commencement of any procedures related to the study. This study complies with all applicable laws regarding patient privacy, and no patient-identifying information will be disclosed in the study results. No identifying information is included in this manuscript.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}